Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin.

Granit, Avital; Mishra, Kumudesh; Barasch, Dinorah; Peretz-Yablonsky, Tamar; Eyal, Sara; Kakhlon, Or

Granit, Avital; Mishra, Kumudesh; Barasch, Dinorah; Peretz-Yablonsky, Tamar; Eyal, Sara; Kakhlon, Or.

Afiliación

Granit A; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Mishra K; Institute for Drug Research School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
Barasch D; Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Peretz-Yablonsky T; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Eyal S; Mass Spectrometry Unit, Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
Kakhlon O; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Front Cell Dev Biol ; 10: 1014798, 2022.

Article en En | MEDLINE | ID: mdl-36544904

Palabras clave

cisplalin; metabolism; metabolomics; triple negative breast cancer; valproic acid

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Cell Dev Biol Año: 2022 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google